Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Current Assets (2019 - 2025)

Avidity Biosciences' Current Assets history spans 7 years, with the latest figure at $1.8 billion for Q4 2025.

  • For Q4 2025, Current Assets rose 16.61% year-over-year to $1.8 billion; the TTM value through Dec 2025 reached $1.8 billion, up 16.61%, while the annual FY2025 figure was $1.8 billion, 16.61% up from the prior year.
  • Current Assets reached $1.8 billion in Q4 2025 per RNA's latest filing, down from $2.0 billion in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $2.0 billion in Q3 2025 to a low of $287.3 million in Q2 2021.
  • Average Current Assets over 5 years is $875.7 million, with a median of $604.2 million recorded in 2023.
  • Peak YoY movement for Current Assets: dropped 18.8% in 2021, then soared 191.97% in 2024.
  • A 5-year view of Current Assets shows it stood at $411.1 million in 2021, then soared by 51.52% to $622.9 million in 2022, then fell by 1.87% to $611.3 million in 2023, then surged by 152.29% to $1.5 billion in 2024, then grew by 16.61% to $1.8 billion in 2025.
  • Per Business Quant, the three most recent readings for RNA's Current Assets are $1.8 billion (Q4 2025), $2.0 billion (Q3 2025), and $1.3 billion (Q2 2025).